Diagnostic Approach to Mesenchymal and Spindle Cell Tumors of the Breast.
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
ppublish
Résumé
Mesenchymal and spindle cell tumors of the breast represent a broad and heterogeneous group of lesions that may be sampled on core needle biopsy or surgical excision. Mesenchymal lesions unique to the breast are those that derive from the specialized breast myofibroblast, such as mammary myofibroblastoma and pseudoangiomatous stromal hyperplasia. However, any mesenchymal lesion arising in extramammary soft tissue may also arise in the breast, including fibroblastic, peripheral nerve sheath, adipocytic, and vascular lesions. The spindle cell lesions pose the greatest diagnostic challenge, due to the significant radiographic, morphologic, and immunophenotypic overlap within the category of mesenchymal lesions and more broadly with other nonmesenchymal breast lesions. The distinction is particularly challenging on the limited material of breast core needle biopsies, and caution should be taken before definitively classifying a breast spindle cell lesion on core needle biopsy to avoid unnecessary treatment if misdiagnosed. Consideration of a wide differential diagnosis, adequate sampling of a resection specimen, use of a targeted immunopanel, and selective use of molecular assays are essential steps for accurate classification of mesenchymal lesions in the breast. This review covers the clinical, histologic, and immunophenotypic features of mesenchymal tumors of the breast, with a special emphasis on the differential diagnoses unique to the breast and challenges encountered on breast core needle biopsy.
Identifiants
pubmed: 39466698
doi: 10.1097/PAP.0000000000000464
pii: 00125480-202411000-00006
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-428Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Sun H, Ding Q, Sahin AA. Immunohistochemistry in the diagnosis and classification of breast tumors. Arch Pathol Lab Med. 2023;147:1119–1132.
Varma S, Shin SJ. An algorithmic approach to spindle cell lesions of the breast. Adv Anat Pathol. 2013;20:95–109.
Tay TKY, Tan PH. Spindle cell lesions of the breast—an approach to diagnosis. Semin Diagn Pathol. 2017;34:400–409.
Rakha EA, Brogi E, Castellano I, et al. Spindle cell lesions of the breast: a diagnostic approach. Virchows Arch. 2022;480:127–145.
Ni Y, Tse GM. Spindle cell lesions of the breast: a diagnostic algorithm. Arch Pathol Lab Med. 2023;147:30–37.
Khoury T. Metaplastic breast carcinoma revisited; subtypes determine outcomes: comprehensive pathologic, clinical, and molecular review. Surg Pathol Clin. 2022;15:159–174.
Tan PH. Fibroepithelial lesions revisited: implications for diagnosis and management. Mod Pathol. 2021;34:15–37.
Li JJX, Tse GM. Core needle biopsy diagnosis of fibroepithelial lesions of the breast: a diagnostic challenge. Pathology. 2020;52:627–634.
Ware AD, Argani P, Cimino-Mathews A. Accuracy and clinical implications of pre-operative breast core needle biopsy diagnoses of fibroepithelial neoplasms and sarcomatoid carcinomas. Breast Cancer Res Treat. 2019;178:51–56.
Magro G. Mammary myofibroblastoma: a tumor with a wide morphologic spectrum. Arch Pathol Lab Med. 2008;132:1813–1820.
McMenamin ME, Fletcher CD. Mammary-type myofibroblastoma of soft tissue: a tumor closely related to spindle cell lipoma. Am J Surg Pathol. 2001;25:1022–1029.
Yan M, Bomeisl P, Gilmore H, et al. Clinicopathological and radiological characterization of myofibroblastoma of breast: a single institutional case review. Ann Diagn Pathol. 2020;48:151591.
Magro G, Longo FR, Salvatorelli L, et al. Lipomatous myofibroblastoma of the breast: case report with diagnostic and histogenetic considerations. Pathologica. 2014;106:36–40.
Howitt BE, Fletcher CD. Mammary-type myofibroblastoma: clinicopathologic characterization in a series of 143 cases. Am J Surg Pathol. 2016;40:361–367.
Magro G, Amico P, Gurrera A. Myxoid myofibroblastoma of the breast with atypical cells: a potential diagnostic pitfall. Virchows Arch. 2007;450:483–485.
Magro G, Gangemi P, Greco P. Deciduoid-like myofibroblastoma of the breast: a potential pitfall of malignancy. Histopathology. 2008;52:652–654.
Magro G. Epithelioid-cell myofibroblastoma of the breast: expanding the morphologic spectrum. Am J Surg Pathol. 2009;33:1085–1092.
D’Alfonso TM, Subramaniyam S, Ginter PS, et al. Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. Hum Pathol. 2016;58:54–61.
Magro G, Foschini MP, Eusebi V. Palisaded myofibroblastoma of the breast: a tumor closely mimicking schwannoma: report of 2 cases. Hum Pathol. 2013;44:1941–1946.
Laforga JB, Escandon J. Schwannoma-like (palisaded) myofibroblastoma: a challenging diagnosis on core biopsy. Breast J. 2017;23:354–356.
D’Alfonso TM, Subramaniyam S, Ginter PS, et al. Characterization of CD34-deficient myofibroblastomas of the breast. Breast J. 2018;24:55–61.
Chen BJ, Mariño-Enríquez A, Fletcher CD, et al. Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications. Am J Surg Pathol. 2012;36:1119–1128.
Alikhassi A, Skarpathiotakis M, Lu FL, et al. Pseudoangiomatous stromal hyperplasia of the breast, imaging and clinical perspective: a review. Breast Dis. 2023;42:147–153.
Virk RK, Khan A. Pseudoangiomatous stromal hyperplasia: an overview. Arch Pathol Lab Med. 2010;134:1070–1074.
Bowman E, Oprea G, Okoli J, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. Breast J. 2012;18:242–247.
Neuman HB, Brogi E, Ebrahim A, et al. Desmoid tumors (fibromatoses) of the breast: a 25-year experience. Ann Surg Oncol. 2008;15:274–280.
Costa PA, Marbin S, Costa B, et al. A nonrandom association of breast implants and the formation of desmoid tumors. Breast J. 2021;27:768–775.
Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway.. Hum Pathol. 2002;33:39–46.
Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509–514.
Lacroix-Triki M, Geyer FC, Lambros MB, et al. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol. 2010;23:1438–1448.
Sawyer EJ, Hanby AM, Poulsom R, et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J Pathol. 2003;200:627–632.
Sawyer EJ, Hanby AM, Rowan AJ, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol. 2002;196:437–444.
Cloutier JM, Kunder CA, Charville GW, et al. Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners. Mod Pathol. 2021;34:1865–1875.
Cloutier JM, Moreland A, Wang L, et al. Low-grade fibromyxoid sarcoma of the breast: genetic characterization and immunohistochemical comparison to morphologic mimics. Hum Pathol. 2023;139:17–26.
Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91:1427–1433.
Blum A, Roehm S. Accessory nipple looks like dermatofibroma in dermoscopy. Arch Dermatol. 2003;139:948–949.
Laharwani H, Prakash V, Walley D, et al. DFSP of the breast: histomorphological, immunohistochemical, and molecular features of a rare case in an unusual location. Appl Immunohistochem Mol Morphol. 2021;29:e73–e82.
Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–587.
Swaby MG, Evans HL, Fletcher CD, et al. Dermatofibrosarcoma protuberans with unusual sarcomatous transformation: a series of 4 cases with molecular confirmation. Am J Dermatopathol. 2011;33:354–360.
Lee PH, Huang SC, Wu PS, et al. Molecular characterization of dermatofibrosarcoma protuberans: the clinicopathologic significance of uncommon fusion gene rearrangements and their diagnostic importance in the exclusively subcutaneous and circumscribed lesions. Am J Surg Pathol. 2022;46:942–955.
Dickson BC, Hornick JL, Fletcher CDM, et al. Dermatofibrosarcoma protuberans with a novel COL6A3-PDGFD fusion gene and apparent predilection for breast. Genes Chromosomes Cancer. 2018;57:437–445.
Bongiorno MR, Doukaki S, Arico M. Neurofibromatosis of the nipple-areolar area: a case series. J Med Case Rep. 2010;4:22.
Fanburg-Smith JC, Meis-Kindblom JM, Fante R, et al. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol. 1998;22:779–794.
Akahane K, Kato K, Ogiso S, et al. Malignant granular cell tumor of the breast: case report and literature review. Breast Cancer. 2015;22:317–323.
Tahir M, Zedan M, Bellamkonda V, et al. Primary malignant peripheral nerve sheath tumor of the breast: a rare case report and review of literature. Cureus. 2022;14:e31586.
Cimino-Mathews A, Subhawong AP, Elwood H, et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol. 2013;44:959–965.
Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4–13.
Le Guellec S, Macagno N, Velasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017;30:1677–1687.
Cleven AH, Sannaa GA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–590.
Yu Q, Cimino-Mathews A, Gross J, et al. Loss of H3K27me3 immunohistochemistry in primary breast neoplasms. Lab Invest. 2023;103:S240.
Lanng C, Eriksen BO, Hoffmann J. Lipoma of the breast: a diagnostic dilemma. Breast. 2004;13:408–411.
Riley MP, Karamchandani DM. Mammary hibernoma: a rare entity. Arch Pathol Lab Med. 2015;139:1565–1567.
Lanng C, Eriksen B, Hoffmann J. Lipoma of the breast: a diagnostic dilemma. Breast. 2004;13:408–411.
Busbaih Z, Almohammed Saleh AA, AlMaghlouth MK, et al. Giant breast lipoma: a case report. Cureus. 2022;14:e22304.
D’Alfonso TM, Shin SJ. Intramuscular lipoma arising within the pectoralis major muscle presenting as a radiographically detected breast mass. Arch Pathol Lab Med. 2011;135:1061–1063.
Babiss E, Cheng E, Mema E. Radiologic and pathologic correlation for angiolipomas of the breast. J Breast Imaging. 2022;4:177–182.
Rosen PP. Vascular tumors of the breast. V. Nonparenchymal hemangiomas of mammary subcutaneous tissues. Am J Surg Pathol. 1985;9:723–729.
Briski LM, Jorns JM. Primary breast atypical lipomatous tumor/ well-differentiated liposarcoma and dedifferentiated liposarcoma. Arch Pathol Lab Med. 2018;142:268–274.
Lyle PL, Bridge JA, Simpson JF, et al. Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification. Histopathology. 2016;68:1040–1045.
Braun A, Solari M, Gattuso P, et al. Benign vascular lesions of the breast: a clinical, radiographic, and pathologic review. Int J Surg Pathol. 2023;31:1437–1448.
Sebastiano C, Gennaro L, Brogi E, et al. Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. Histopathology. 2017;71:795–804.
Ferreli C, Atzori L, Caputo V, et al. Diffuse dermal angiomatosis of the breast: an emerging entity in the setting of cutaneous reactive angiomatoses. Clin Dermatol. 2021;39:271–277.
Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol. 2005;29:983–996.
Rutland CD, Bean GR, Charville GW. Contemporary diagnostic approach to atypical vascular lesion and angiosarcoma. Semin Diagn Pathol. 2023;40:284–294.
Motaparthi K, Lauer SR, Patel RM, et al. MYC gene amplification by fluorescence in situ hybridization and MYC protein expression by immunohistochemistry in the diagnosis of cutaneous angiosarcoma: systematic review and appropriate use criteria. J Cutan Pathol. 2021;48:578–586.
Olander S, Wennstig AK, Garmo H, et al. Angiosarcoma in the breast: a population-based cohort from Sweden. Br J Surg. 2023;110:1850–1856.
Yin M, Wang W, Drabick JJ, et al. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer. 2017;17:295.
Teng L, Yan S, Du J, et al. Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis. World J Surg Oncol. 2023;21:144.
Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol. 1998;22:683–697.
Kuba MG, Dermawan JK, Xu B, et al. Histopathologic grading is of prognostic significance in primary angiosarcoma of breast: proposal of a simplified 2-tier grading system. Am J Surg Pathol. 2023;47:307–317.
Fraga-Guedes C, André S, Mastropasqua MG, et al. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression. Breast Cancer Res Treat. 2015;151:131–140.